Proactive Investors - Run By Investors For Investors

Novogen to strengthen patent position

Novogen to strengthen patent position

Novogen (ASX:NRT; NASDAQ:NVGN) will strengthen its intellectual property position on its key anti-tropomyosin technology platform, lodging two new patents.

Novogen has two drug technology platforms, the Superbenzopyran (SBP) and anti-tropomyosin (ATM) with established patent positions.

Acting CEO Iain Ross, said the company currently had an extensive program of activities underway including the lead pre-clinical programs and discovery programs.

The medicinal chemistry programs have identified two promising drug candidates (Cantrixil and Anisina), which Novogen is progressing down the translational development path.

Novogen is searching for a world class CEO and to beef up its project and manufacturing management support ranks.

The company held $45 million in cash in June.

 


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full NRT profile View Profile

Novogen Ltd Timeline

Newswire
August 05 2015

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use